<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03962387</url>
  </required_header>
  <id_info>
    <org_study_id>K0102-E</org_study_id>
    <nct_id>NCT03962387</nct_id>
  </id_info>
  <brief_title>Evalution the Safety and Efficacy in Atopic Dermatitis Patients</brief_title>
  <official_title>A Multi-center, Open, Long-term Follow-up Study to Evaluate the Efficacy and Safety of FURESTEM-AD Inj. in Patients With Moderate to Severe Chronic Atopic Dermatitis: 5-year Results From the K0102 Extension Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kang Stem Biotech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kang Stem Biotech Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-center, open, long-term follow-up study to evaluate the efficacy and safety of
      FURESTEM-AD inj. in patients with moderate to severe chronic atopic dermatitis: 5-year
      results from the K0102 extension study
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 5, 2019</start_date>
  <completion_date type="Anticipated">January 2, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Assessment (Rate of Adverse Event, Number of Participants with Adverse Event)</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects whose Eczema Area and Severity Index (EASI) was decreased from baseline by more than 50% at Week 12 (EASI-50)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects whose Eczema Area and Severity Index (EASI) was decreased from baseline by more than 75% at Week 12 (EASI-75)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in EASI from baseline</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EASI from baseline</measure>
    <time_frame>3 years</time_frame>
    <description>EASI range is from 0 (clear) to 72 (severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects whose Investigator's Global Assessment (IGA) score at each visit is 0 or 1</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects whose IGA at each visit is 0 or 1, or improved to 2 or higher</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects whose SCORing Atopic Dermatitis (SCORAD) INDEX was decreased from baseline by more than 50% at each visit (SCORAD-50)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in SCORAD index from baseline at each visit</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SCORAD index from baseline at each visit</measure>
    <time_frame>3 years</time_frame>
    <description>SCORAD index range is from 0 (clear) to 103 (severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in Body Surface Area(BSA) of the lesion from baseline</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Surface Area(BSA) of the lesion from baseline</measure>
    <time_frame>3 years</time_frame>
    <description>BSA range is from 0 (clear) to 100 (severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total serum Immunoglobulin E(IgE) from baseline</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">194</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Atopic Dermatitis</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Not applicable(observational study)</intervention_name>
    <description>Not applicable(observational study)</description>
    <arm_group_label>Atopic Dermatitis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        moderate to severe chronic atopic dermatitis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject who enrolled K0102 Clinical Trial(parent study).

          2. Subjects who understand and voluntarily sign an informed consent form

        Exclusion Criteria:

          1. In case follow-up is not possible from end of K0102 clinical trial to end of this
             study period

          2. Any other condition which the investigator judges would make patient unsuitable for
             study participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Seulbi Lee</last_name>
    <phone>+82-2-888-1592</phone>
    <email>sblee@kangstem.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeong-hyang Woo</last_name>
    <phone>+82-2-888-1592</phone>
    <email>jhwoo@kangstem.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul ST. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dae-eun Cho</last_name>
      <phone>+82-2-22588196</phone>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>November 28, 2018</study_first_submitted>
  <study_first_submitted_qc>May 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2019</study_first_posted>
  <last_update_submitted>May 23, 2019</last_update_submitted>
  <last_update_submitted_qc>May 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

